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The aim of this study was to investigate the relationship of
cyclooxygenase (COX)-2 and p53 expression with prognosis
in patients with conventional renal cell carcinoma (RCC). For-
malin-fixed, paraffin-embedded tissue sections of conventional
RCC from 92 patients, who had undergone radical nephrec-
tomy, were examined for COX-2 and p53 expression by
immunohistochemistry and compared with clinicopathological
variables. The COX-2 expression significantly correlated only
with tumor size (p=0.049), whereas the p53 expression pro-
foundly correlated with the TNM stage (p=0.024), M stage
(p=0.001), and metastasis (synchronous or metachronous; p=
0.004). The COX-2 overexpression did not significantly asso-
ciate with p53 positivity (p=0.821). The survival rate of
patients correlated with the p53 expression (p<0.0001) but not
with the COX-2 expression (p=0.7506). Multivariate analyses
indicated that tumor size, M stage, and p53 expression were
independent prognostic factors for cancer-specific survival.
The COX-2 expression was not an independent factor. These
results show that the increased expression of p53 was asso-
ciated with metastasis and a worse prognosis in conventional
RCC, which suggests that p53 might have played an important
role in the progression of conventional RCC. The increased
expression of COX-2 was associated only with tumor size, but
may not be an important prognostic factor in conventional
RCC. No association was observed between COX-2 over-
expression and p53 positivity in conventional RCC.
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INTRODUCTION
The renal cell carcinoma (RCC) is the most com-
mon malignant tumor of the adult kidney, and its
incidence is increasing.
1 To date, tumor stage and
grade have been considered the most important
prognostic parameters for patients with RCC.
However, in many cases, these parameters were
insufficient to predict the clinical behavior of RCC
tumors.
2,3 Therefore, it is important to identify
additional indicators of the biological aggres-
siveness of RCC.
Cyclooxygenase (COX) catalyzes the synthesis
of prostaglandins from arachidonic acid. There are
two isoforms of COX: COX-1 and COX-2. While
COX-1 is constitutively expressed, COX-2 is in-
duced by various stimuli such as the cytokines,
growth factors, and tumor promoters.
4,5 The COX-
2 levels have been shown to increase in several
types of human cancers like the ones which
develop in the gastrointestinal tract, breast, cervix,
lung, prostate, and bladder.
6-12 This suggests that
the COX-2 may play an important role in the can-
cer progression by affecting tumor cell prolifera-
tion, resistance to apoptosis, angiogenesis, immu-
nosuppression, and tumor invasion.
7,13-15 How-
ever, the relationship between the COX-2 expres-
sion and RCC remains unclear. Although the
COX-2 is highly expressed in canine RCC,
16 it is
down-regulated in RCC in the Eker (TSC2 gene
mutant) rat model.
17 The COX-2 is highly ex-
pressed in human RCC, but the results of its cor-
relation with tumor stage and grade have been
contradictory.
18,19
Apoptosis is a critical pathway that selectively
allows certain cells with damaged DNA to un-
dergo cell death. Abnormalities in this pathway
may lead to uncontrolled cellular proliferation
and, ultimately, to carcinogenesis. p53 is a known
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inducer of apoptosis, and it is the most common
genetic mutant found in cancers. There are wide
variations in the reported incidence of p53 related
mutations in RCC, and its prognostic significance
for this type of cancer remains controversial. Some
researchers have reported that p53 mutations in
the case of RCC may be used as a prognostic fac-
tor,
20,21 but others disagreed.
22,23 Recent evidences
have suggested that COX-2 may also inhibit
apoptosis.
13
In the present study, the expressions of COX-2
and p53 was investigated, and their relationships
to clinicopathological variables in patients with
conventional RCC were evaluated.
MATERIALS AND METHODS
Patients and specimens
Formalin-fixed, paraffin-embedded, archival sur-
gical specimens that had been obtained from 92
patients (71 men and 21 women; mean age, 54.8
years; range, 26 - 81 years) who had received a
diagnosis of primary conventional RCC were
studied. All patients underwent radical nephrec-
tomy at our institution between January 1995 and
September 2002. During the lymphadenectomy,
only the renal hilar lymph nodes were routinely
removed. Whenever an enlarged lymph node was
observed during surgery, a node dissection clear-
ing the ipsilateral great vessel and the renal hilum
was performed. Tumors were staged according to
the 1997 revised TNM system,
24 and were graded
according to Fuhrman's nuclear grading system.
25
Immunohistochemistry
Paraffin-embedded blocks were sectioned at 4-
μm thickness, deparaffinized, and rehydrated.
After microwave pretreatment in citrate buffer
(pH 6.0) for antigen retrieval, slides were im-
mersed in 3% hydrogen peroxide for 10 minutes
to block the endogenous peroxidase activity. The
sections were blocked for 10 minutes with block-
ing reagent using the Cap-Plus
TM Detection Kit
(ZYMED, San Francisco, CA, USA). Sections were
then incubated manually with goat monoclonal
antibody to COX-2 (diluted 1 : 200; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 1 hour
at 37 or with mouse monoclonal antibody to
p53 (diluted 1 : 20; Novo Castra, Newcastle, UK)
overnight at 4 in a humidified chamber. After
a second incubation with a biotinylated secondary
antibody, slides were incubated with peroxidase-
conjugated streptavidin (DAKO LSAB+ Kit;
DAKO Corp., Carpinteria, CA, USA) for COX-2 or
the Cap-Plus
TM Detection Kit (ZYMED) for p53.
Reaction products were visualized by immersing
the slides in diaminobenzidine tetrachloride and
then counterstaining them with Mayer's hema-
toxylin. The positive staining of smooth muscle
cells from blood vessels provided an internal posi-
tive control for COX-2 immunostaining. The colon
carcinoma samples with known p53 mutations
and documented accumulation of p53 by immu-
nohistochemistry were used as positive control for
p53. Negative controls were obtained by omitting
the primary antibody.
Evaluation of immunohistochemical staining
The immunostaining was independently evalu-
ated by two pathologists who were unaware of
the clinical data. The COX-2 expression was based
on the presence of the cytoplasmic staining, which
was semi-quantitatively estimated according to
the methods described by Sinicrope et al.,
26 with
minor modifications. On the basis of the percen-
tages of immunopositive cells, the data were sub-
divided into five categories as follows: (0) 10%;
(1) 11 - 25%; (2) 26 - 50%; (3) 51 - 75%; and (4) >
75% positive cells. The immunointensity was also
subclassified into four categories: (0) negative; (1)
weak; (2) moderate (same intensity of smooth
muscle cells); and (3) strong (Fig. 1). The immu-
noreactive scores for each case were generated by
multiplying the values of the two parameters,
which were then stratified into three groups:
weak (scores 0 - 4), moderate (scores 5 - 8), and
strong (scores 9 - 12) COX-2 expression for the
survival analysis. The p53 immunostaining was
considered to be positive when 10% or more of
the tumor cell nuclei were stained (Fig. 2).
Statistical analysis
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square test was used to analyze the correlation
between COX-2 or p53 expression and various
clinicopathological variables. The relationship
between COX-2 and p53 expression was evalu-
ated by the Mann-Whitney U-test. The paired
t-test or McNemar test was used for the correla-
tion of the primary and metastatic sites in the
expression of the COX-2 or p53. The survival
calculations were illustrated with Kaplan-Meier
curves, and univariate and multivariate analyses
were performed using the log-rank test or the
Cox proportional-hazards regression model. The
values of p<0.05 were considered to be statis-
tically significant in all of the analyses.
RESULTS
The clinicopathological characteristics of the 92
patients are summarized in Table 1. Sixty-seven
patients were disease-free at a median follow-up
of 36 months (range, 12 - 96 months); the other 25
patients had either synchronous metastases (n=12)
at the time of nephrectomy or metachronous
metastases (n=13) a median of 23 months (range,
4 - 72 months) after nephrectomy. Fourteen pa-
tients died during the follow-up period, 7 with
synchronous metastases and 7 with metachronous
metastases. For 18 of the 25 patients with metas-
tases, their metastases were confirmed histopatho-
logically.
Of the 92 sections, the COX-2 expression (im-
Fig. 1. Immunohistochemical staining for COX-2. (A) COX-2 immunostaining was not seen (COX-2 intensity, 0). (B) Almost
all cancer cell cytoplasms strongly stained for COX-2 (COX-2 intensity, 3). Original magnification, × 400.
Fig. 2. Immunohistochemical staining for p53. (A) Tumor cells showed no nuclear staining for p53 (p53 negative). (B) A
strong nuclear expression of p53 was seen (p53 positive). Original magnification, × 400.
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munoreactive scores) was weak in 17 (18.5%),
moderate in 21 (22.8%), and strong in 54 (58.7%).
Positive immunostaining for p53 was observed in
11 (12.0%) of the 92 sections.
Because only 1 patient had lymph node metas-
tasis, the analysis according to the lymph node
status was not performed. The COX-2 expression
significantly correlated with the tumor size (p=
0.049) but not with the TNM stage (p=0.541), T
stage (p=0.368), M stage (p=0.394), grade (p=0.658),
or metastasis (synchronous or metachronous; p=
0.564). The p53 expression profoundly correlated
with the TNM stage (p=0.024), M stage (p=0.001),
and metastasis (p=0.004) but not with the tumor
size (p=0.777), T stage (p=0.480), or grade (p=
0.829) (Table 2).
The COX-2 overexpression did not significantly
associate with p53 positivity (p=0.821). The ex-
pressions of COX-2 (p=0.476) and p53 (p=0.125)
were not significantly different between the pri-
mary and metastatic sites. A Kaplan-Meier survi-
val curve showed that the survival rate of patients
with p53-positive tumors was significantly lower
than that of patients with p53-negative tumors (p
< 0.0001) (Fig. 3). There was no difference in the
survival rates according to the level of the COX-2
expression (p=0.7506) (Fig. 4).
The univariate analyses identified tumor size,
TNM stage, T stage, M stage, and p53 expression
as significant prognostic factors for cancer-specific
survival, whereas the multivariate analyses indi-
cated that tumor size (p=0.002), M stage (p<0.001),
and p53 expression (p=0.016) were independent
prognostic factors. The COX-2 expression was not
an independent factor (Table 3).
DISCUSSION
An elevated COX-2 expression has been ob-
Table 1. Clinicopathological Data of 92 Patients with
Conventional Renal Cell Carcinoma
Characteristics No. (%)
TNM stage
I
II
III
IV
43 (46.7)
11 (12.0)
25 (27.2)
13 (14.1)
T stage
T1
T2
T3
T4
48 (52.1)
11 (12.0)
31 (33.7)
2 (2.2)
N stage
N0
N1
91 (98.9)
1 (1.1)
M stage
M0
M1
80 (87.0)
12 (13.0)
Grade
1
2
3
4
5 (5.4)
14 (15.2)
61 (66.3)
12 (13.0)
Metastasis (synchronous or metachronous)
No
Yes
67 (72.8)
25 (27.2)
Fig. 3. Kaplan-Meier cancer-specific survival curves
according to the p53 expression. The survival rate of
patients with p53-positive tumors was significantly lower
than that of patients with p53-negative tumors (p <
0.0001).Table 3. Univariate and Multivariate Survival Analysis of 92 Patients with Conventional Renal Cell Carcinoma
Variables
Univariate Multivariate
p Hazards ratio p
Tumor size 0.0003 13.510 0.002
TNM Stage 0.0008 1.267 0.863
T stage 0.0146 0.536 0.590
M stage <0.0001 18.267 <0.001
Grade 0.1237 2.365 0.429
COX-2 0.7506 0.778 0.573
p53 <0.0001 5.432 0.016
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Table 2. Relationship between COX-2 or p53 Expression and Clinicopathological Variables in 92 Patients with
Conventional Renal Cell Carcinoma
Variables No. of patients
COX-2 immunoreactive
scores
p No. (%) of p53-positive tumors p
Tumor size
7 cm 62 2.29 ± 0.80
0.049*
7 (11.3)
0.777
> 7 cm 30 2.63 ± 0.72 4 (13.3)
TNM stage
Low (I + II) 54 2.44 ± 0.77
0.541
3 (5.6)
0.024*
High (III + IV) 38 2.34 ± 0.81 8 (21.1)
T stage
Low (T1 + T2) 59 2.46 ± 0.75
0.368
6 (10.2)
0.480
High (T3 + T4) 33 2.30 ± 0.85 5 (15.2)
M stage
M0 80 2.38 ± 0.80
0.394
6 (7.5)
0.001*
M1 12 2.58 ± 0.67 5 (41.7)
Grade
Low (G1 + G2) 19 2.47 ± 0.84
0.658
2 (10.5)
0.829
High (G3 + G4) 73 2.38 ± 0.78 9 (12.3)
Metastasis
No 67 2.37 ± 0.79
0.564
4 (6.0)
0.004*
Yes 25 2.48 ± 0.77 7 (28.0)
Metastasis, synchronous or metachronous metastasis.
*statistically significantDae Sung Cho, et al. 138
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served in several types of human cancers, and the
overexpression of the COX-2 has been shown to
correlate with carcinogenesis and poor prognostic
outcome.
6-12 However, past studies in RCC have
been limited, and the relationship between the
COX-2 expression and RCC remains unclear.
Khan et al.
16 showed that COX-2 was overex-
pressed in 2 of 3 dogs with spontaneously de-
veloped RCC, which suggested that COX-2 might
play a role in the modulation of neoplastic cell
growth. Conversely, Okamoto et al.
17 found that
COX-2 mRNA expression was down-regulated in
8 of 10 spontaneously developed RCCs of Eker
(TSC2 gene mutant) rats and that it was not
down-regulated, but showed almost the same
intensity as in the normal kidney in the other two
rats.
With regard to the human RCC, Hara et al.
27
showed that COX-2 was overexpressed in RCC
but that the expression levels did not correlate
with cancer grade. In RCC, the immunoreactive
signals in granular cell subtypes were stronger
than those in clear cell subtypes. Miyata et al.
18
found that increased COX-2 expression was
observed in 70 (53.4%) of 131 patients with RCC.
Among the patients, 84% had conventional RCC.
The COX-2 expression significantly associated
with various clinicopathological variables, in-
cluding the T stage, N stage, M stage, and tumor
grade. It was correlated with the Ki-67 labeling
index, microvessel density, and MMP-2 expres-
sion but not with the apoptotic index. The COX-2
expression was identified as an independent risk
factor for large tumor size (> 7 cm) but not an
independent prognostic factor for cancer-specific
survival, which suggested that the COX-2 is not
a significant prognostic factor in RCC.
In the present study, only the conventional RCC
was studied in order to exclude the influence of
the histologic type. The COX-2 expression was
moderate or strong in 75 (81.5%) of the 92 RCC
samples. The COX-2 expression significantly cor-
related with the tumor size but not with the TNM
stage, T stage, M stage, grade, or metastasis (syn-
chronous or metachronous). There was no dif-
ference in the survival rates according to the level
of the COX-2 expression. The COX-2 expression
was not an independent prognostic factor for can-
cer-specific survival according to our multivariate
analysis. The results show that COX-2 is not an
important prognostic factor in conventional RCC.
These results are in agreement with those of
Yoshimura et al.
19 who reported that COX-2 over-
expression was detected in RCC tissues but was
not associated with tumor stage or grade. The
findings of the present study are also in keeping
with the results of Miyata et al.
18 that the COX-2
expression was associated with tumor size but
was not an independent prognostic factor for
cancer-specific survival.
Recent evidences have suggested that COX-2
contributes to the inhibition of apoptosis.
13 The
possible mechanism of the COX-2 inhibition of
apoptosis involves the generation of prostaglan-
din products or the removal of the substrate
arachidonic acid via COX-2 catalytic activity.
28,29
p53 is a known inducer of apoptosis, and its
prognostic significance for RCC remains contro-
versial.
20-23 In the current study, the p53 expres-
sion significantly correlated with the TNM stage,
M stage, and metastasis (synchronous or meta-
chronous). The survival rate of patients with p53-
positive tumors was significantly lower than that
of patients with p53-negative tumors. The p53
Fig. 4. Kaplan-Meier cancer-specific survival curves
according to the COX-2 expression. There was no dif-
ference in survival rates according to the level of the
COX-2 expression (p=0.7506). Weak, scores 0 - 4; mode-
rate, scores 5-8; strong, scores 9-12.Cyclooxygenase-2 and p53 Expression in Renal Cell Carcinoma 139
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expression, together with tumor size and M stage,
was an independent prognostic factor for cancer-
specific survival according to the results of the
multivariate analysis conducted in this study.
However, p53 positivity did not significantly asso-
ciate with the COX-2 overexpression, and that was
in harmony with the results of Miyata et al.
18 that
the COX-2 expression did not correlate with the
apoptotic index.
In conclusion, the increased expression of p53
was associated with metastasis and a worse pro-
gnosis in the conventional RCC, which suggested
that p53 might have played an important role in
the progression of the conventional RCC. How-
ever, the increased expression of the COX-2 was
only associated with tumor size, but may not be
an important prognostic factor in the conventional
RCC. There was no association between the COX-
2 overexpression and p53 positivity in the con-
ventional RCC.
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